Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 16 of 95, showing 5 Applications out of 471 total, starting on record 76, ending on 80

# Protocol No Study Title Investigator(s) & Site(s)

76.

ECCT/23/05/02   A5384
    A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM)   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View

77.

ECCT/23/05/01   A5356
    A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
MOI UNIVERSITY CLINICAL RESEARCH CENTRE
 
View

78.

ECCT/23/04/05   BiMVaC01
    A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults.   
Principal Investigator(s)
1. NDUNGU FRANCIS
2. Said Jongo
Site(s) in Kenya
KEMRI-CGMRC Kilifi
 
View

79.

ECCT/23/04/04   AGREE
    Oral antenatal L-citrulline supplementation to reduce adverse pregnancy outcomes: a two-arm, randomized, placebo-controlled multi-site trial in Kenya   
Principal Investigator(s)
1. Hellen Barsosio
Site(s) in Kenya
1. Ahero County Hospital (Kisumu county)
2. Alupe sub-county Hospital (Busia county)
3. Siaya County Referral Hospital (Siaya county)
 
View

80.

ECCT/23/04/03   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19   
Principal Investigator(s)
1. Prof Abraham Mosigisi Siika
Site(s) in Kenya
1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenyatta National Hospital (Nairobi City county)
4. KEMRI CCR – BUTERE SITE (Kakamega county)
5. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
6. KEMRI – AHERO Clinical Trials Units (Kisumu county)
 
View